Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Maxcyte Inc (MXCT)

Maxcyte Inc (MXCT)
3.41 +0.07 (+2.10%) 03/03/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 3.32 -0.09 (-2.64%) 16:49 ET
Quote Overview for Mon, Mar 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.31
Day High
3.46
Open 3.36
Previous Close 3.34 3.34
Volume 848,100 848,100
Avg Vol 468,410 468,410
Stochastic %K 5.77% 5.77%
Weighted Alpha -24.63 -24.63
5-Day Change -0.36 (-9.55%) -0.36 (-9.55%)
52-Week Range 3.16 - 5.26 3.16 - 5.26
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 353,526
  • Shares Outstanding, K 105,846
  • Annual Sales, $ 41,290 K
  • Annual Income, $ -37,920 K
  • EBIT $ -42 M
  • EBITDA $ -45 M
  • 60-Month Beta 1.30
  • Price/Sales 7.65
  • Price/Cash Flow N/A
  • Price/Book 1.69

Options Overview Details

View History
  • Implied Volatility 310.69% ( -138.14%)
  • Historical Volatility 42.56%
  • IV Percentile 92%
  • IV Rank 64.97%
  • IV High 467.20% on 04/05/24
  • IV Low 20.43% on 05/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 199
  • Open Int (30-Day) 334

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.15
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -180.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.31 +3.02%
on 03/03/25
Period Open: 4.35
4.67 -26.98%
on 02/06/25
-0.94 (-21.61%)
since 02/03/25
3-Month
3.31 +3.02%
on 03/03/25
Period Open: 3.58
5.20 -34.42%
on 01/21/25
-0.17 (-4.75%)
since 12/03/24
52-Week
3.16 +7.74%
on 11/19/24
Period Open: 4.71
5.26 -35.17%
on 06/11/24
-1.30 (-27.60%)
since 03/01/24

Most Recent Stories

More News
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MXCN.LN : 680.000 (unch)
MXCT.LN : 268.000 (+1.52%)
MXCT : 3.41 (+2.10%)
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

MXCN.LN : 680.000 (unch)
MXCT.LN : 268.000 (+1.52%)
MXCT : 3.41 (+2.10%)
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

MXCN.LN : 680.000 (unch)
MXCT.LN : 268.000 (+1.52%)
MXCT : 3.41 (+2.10%)
MarketBeat Week in Review – 01/20 - 01/24

Stocks surged higher as investors reacted positively to dovish tariff news; next week will be highlighted by the Federal Reserve meeting and some tech earnings

NFLX : 973.70 (-0.70%)
META : 655.05 (-1.97%)
AAPL : 238.03 (-1.58%)
NRG : 100.25 (-5.17%)
SMCI : 36.07 (-13.00%)
ORCL : 162.02 (-2.43%)
SOUN : 10.32 (-4.62%)
QCOM : 153.62 (-2.26%)
MXCT : 3.41 (+2.10%)
FCX : 35.53 (-3.74%)
DUK : 118.67 (+1.00%)
TEM : 50.93 (-9.34%)
MaxCyte: Building the Future of Cell and Gene Therapy Innovation

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.

CRSP : 42.29 (-3.71%)
MXCT : 3.41 (+2.10%)
VRTX : 483.31 (+0.73%)
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

MXCN.LN : 680.000 (unch)
MXCT.LN : 268.000 (+1.52%)
MXCT : 3.41 (+2.10%)
MaxCyte Announces Retirement of Board Member Art Mandell

MXCN.LN : 680.000 (unch)
MXCT.LN : 268.000 (+1.52%)
MXCT : 3.41 (+2.10%)
MaxCyte Completes Operational Review, Adjusts Workforce, and Raises 2024 Revenue Guidance

MaxCyte completes operational review, streamlines workforce, increases 2024 revenue guidance, and focuses on cell therapy innovation.Quiver AI SummaryMaxCyte, Inc. has completed an internal operational...

MXCT : 3.41 (+2.10%)
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

MXCN.LN : 680.000 (unch)
MXCT.LN : 268.000 (+1.52%)
MXCT : 3.41 (+2.10%)
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MXCN.LN : 680.000 (unch)
MXCT.LN : 268.000 (+1.52%)
MXCT : 3.41 (+2.10%)

Business Summary

MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.

See More

Key Turning Points

3rd Resistance Point 3.63
2nd Resistance Point 3.54
1st Resistance Point 3.48
Last Price 3.41
1st Support Level 3.33
2nd Support Level 3.24
3rd Support Level 3.18

See More

52-Week High 5.26
Fibonacci 61.8% 4.46
Fibonacci 50% 4.21
Fibonacci 38.2% 3.97
Last Price 3.41
52-Week Low 3.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements